Select Bibliography

Select Bibliography

Filter by any of these (after searching):

Federally Funded Research

Blood

There are 144 items

Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)

Google Scholar

Advani, Anjali S. , Sanford, Ben , Luger, Selina , Devidas, Meenakshi ... - ASH - Blood - 2013

Abstract - Secondary Endpoint - Primary Analysis - Leukemia - C10403

Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502

Google Scholar

Attar, E. C. , Donohue, K. A. , Amrein, P. C. , Wadleigh, M. ... - - Blood - 2010

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-10502

Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study

Google Scholar

Attar, E. C. , Maharry, K. , Mrozek, K. , Radmacher, M. D. ... - ASH - Blood - 2009

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10502 , CALGB-20202 , CALGB-20502 , CALGB-8461

Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients >= 60 years (CALGB 9720)

Google Scholar

Baer, M. R. , George, S. L. , Sanford, B. L. , Bothun, S. M. ... - - Blood - 2007

Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-8461 , CALGB-9720

Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study

Google Scholar

Becker, H. , Maharry, K. , Radmacher, M. D. , Margeson, D. ... - - Blood - 2010

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (>= 60 years y ) and Younger (< 60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study

Google Scholar

Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. D. ... - - Blood - 2009

Abstract - Primary Endpoint - Primary Analysis - Correl Sci NOS - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

PubMed

PMC

QxMD

DOI

Google Scholar

Becker, Heiko , Marcucci, Guido , Maharry, Kati ... - - Blood - 2010

Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

Acute myeloid leukemia (AML) patients with an isolated trisomy display increased frequency of spliceosome mutations CALGB 8461 and 20202 (Alliance)

Google Scholar

Bhatnagar, Bhavana , Eisfeld, Ann-Kathrin , Mrózek, Krzysztof ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461

Mutational Landscape and Clinical Outcome Associated with Different Rearrangements Involving 11q23/MLL in De Novo Acute Myeloid Leukemia (AML) CALB 8461 and 20202 (Alliance)

Google Scholar

Bill, Marius , Eisfeld Ann-Kathrin , Mrózek Krzysztof ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461

A 17-gene leukemia stem cell (LSC) score in adult patients (pts) with acute myeloid leukemia (AML) reveals a distinct mutational landscape and refines current European Leukemianet (ELN) genetic risk stratification (Alliance)

DOI

Google Scholar

Bill, Marius , Nicolet, Deedra , Eisfeld, Ann-Kathrin ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461

Prognostic and biologic significance of transfer RNA-derived small RNAs(tsRNAs) expression in younger adult patients (pts) with cytogenetically normal acute myeloid leukemia (CN-AML)

DOI

Google Scholar

Bill, Marius , Veneziano, Dario , Kohlschmidt, Jessica ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , C9665 , CALGB-20202

Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502

Google Scholar

Blum, K. A. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2008

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50502

Challenges for conducting clinical trials evaluating maintenance chemotherapy in acute myeloid leukemia (AML): a Cancer and Leukemia Group B (CALGB) study

Google Scholar

Blum, W. , Donohue, K. , Marcucci, G. , Deangelo, D. J. , Uy, G. L. ... - ASH - Blood - 2010

Abstract - No-Endpoint Endpoint - Comprehensive Analysis - Leukemia - CALGB-10503

Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)

Google Scholar

Blum, W. , Sanford, B. , Klisovic, R. B. , Deangelo, D. J. , Uy, G. ... - ASH - Blood - 2012

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10503

Obesity Is An Adverse Prognostic Factor For Overall and Disease-Free Survival In Adult Acute Promyelocytic Leukemia But Not In Acute Myeloid Leukemia: A Pooled Analysis From Four Alliance Prospective Studies

Google Scholar

Castillo, Jorge J. , Mulkey, Flora , Geyer, Susan ... - - Blood - 2013

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - CALGB-9621 , CALGB-9710 , CALGB-10503 , CALGB-19808

Acute Myeloid Leukemia (AML) with 9q aberrations occuring within a non-complex karyotype is highly associated with CEBPA and NPM1 mutations - A joint analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB)

Google Scholar

Corbacioglu, A. , Frohling, S. , Paschka, P. , Marcucci, G. ... - ASH - Blood - 2007

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-8461 , CALGB-9621 , CALGB-9665

FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R]

Google Scholar

Czuczman, M. S. , Leonard, J. P. , Johnson, J. L. , Jung, S.-H. ... - - Blood - 2008

Abstract - Secondary Endpoint - Primary Analysis - Lymphoma - CALGB-50402

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

PubMed

PMC

QxMD

DOI

Google Scholar

DeAngelo, Daniel J. , Yu, Daohai , Johnson, Jeffrey L. ... - - Blood - 2007

Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19801

Allosteric Akt inhibitor MK2206 synergizes with bendamustine in promoting the apoptosis of chronic lymphocytic leukemia cells and selectively targets B-cell receptor mediated cytokine production

Google Scholar

Ding, W. , Shanafelt, T. D. , Lesnick, C. , Sassoon, T. , Secreto, C. ... - ASH - Blood - 2012

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - N1087

The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)

Google Scholar

Ding, Wei , Shanafelt, Tait D. , Zent, Clive S. , Leis, Jose F. ... - - Blood - 2013

Abstract - Primary Endpoint - Primary Analysis - Leukemia - N1087

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.

PubMed

DOI

Google Scholar

Döhner, Konstanze , Thiede, Christian , Jahn, Nikolaus ... - - Blood - 2019

Manuscript - No-Endpoint Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10603

Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients treated within the RATIFY/CALGB 10603 (Alliance) Study

Google Scholar

Döhner, Konstanze , Thiede, Christian , Larson, Richard A. ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603

Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16)

Google Scholar

Edwards, C. G. , Maharry, K. , Mrozek, K. , Schwind, S. , Paschka, P. ... - - Blood - 2011

Abstract - Primary Endpoint - Comprehensive Analysis - Leuk Corr Sci - CALGB-10503 , CALGB-19808 , CALGB-9621

Additional gene mutations refine the 2017 European Leukemianet (ELN) classification of adult patients (pts) with de novo acute myeloid leukemia (AML) aged <60 years: An analysis of Alliance studies

DOI

Google Scholar

Eisfeld, Ann-Kathrin , Kohlschmidt, Jessica , Mrózek, Krzysztof ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , CALGB-20202

Mutations in genes associated with familial predisposition to myeloid neoplasms:their frequency and associations with pretreatment characteristics in adult patients (pts) with presumably sporadic de novo acute myeloid leukemia (AML) (Alliance)

DOI

Google Scholar

Eisfeld, Ann-Kathrin , Kohlschmidt, Jessica , Mrózek, Krzysztof ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , CALGB-20202

MiR-3151, a novel microRNA embedded in BAALC, is only weakly co-xxpressed with its host gene and independently impacts on the clinical outcome of older patients (pts) with de novo cytogenetically normal acute myeloid leukemia (CN-AML)

Google Scholar

Eisfeld, Ann-Kathrin , Marcucci, G. , Maharry, K. , Schwind, S. ... - - Blood - 2011

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-8923 , CALGB-9420 , CALGB-9720

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia

PubMed

PMC

QxMD

DOI

Google Scholar

Eisfeld, Ann-Kathrin , Marcucci, Guido , Maharry, Kati ... - - Blood - 2012

Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-9665

A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study

Google Scholar

Farag, S. , Owzar, K. , Hars, V. , Lazarus, H. M. , Stadtmauer, E. A. ... - ASH - Blood - 2009

Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-100101

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Google Scholar

Fulton, Noreen , Johnson, Jeffrey , Kaplan, Lawrence D. , Koval, Greg ... - ASH - Blood - 2013

Abstract - Secondary Endpoint - Primary Analysis - Lymphoma - CALGB-50403

Treatment-influenced associations of PML-RARalpha mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

PubMed

PMC

QxMD

Google Scholar

Gallagher, R. E. , Moser, B. K. , Racevskis, J. , Poire, X. ... - - Blood - 2012

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C9710

Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710

Google Scholar

Gallagher, R. E. , Moser, B. K. , Racevskis, J. , Poire, X. ... - - Blood - 2010

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C9710

Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)

Google Scholar

Grant, B. , Leonard, J. P. , Johnson, J. L. , Kostakoglu, L. , Hsi, E. ... - - Blood - 2010

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50701

Dual Epigenetic Control of CCAAT/Enhancer Binding Protein {alpha} (C/EBP{alpha}) Expression in Acute Myeloid Leukemia

Google Scholar

Hackanson, B. , Bennett, K. L. , Brena, R. M. , Jiang, J. ... - - Blood - 2007

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia

PubMed

PMC

QxMD

DOI

Google Scholar

Hickey, Christopher J. , Schwind, Sebastian , Radomska, Hanna S. ... - - Blood - 2013

Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-9621 , CALGB-19808

Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study

Google Scholar

Hsi, E. D. , Said, J. , Johnson, J. L. , Jung, S. , Lai, R. , Jones, D. ... - ASH - Blood - 2008

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-50103

Comprehensive molecular profiling of FLT3-mutated acute myeloid leukemia (AML) patients treated within the RATIFY trial (Alliance)

DOI

Google Scholar

Jahn, Nikolaus , Panina, Ekaterina , Bullinger, Lars , Dolnik, Anna ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10603

Everolimus plus R-CHOP-21 is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG N1085 (Alliance)

Google Scholar

Johnston, Patrick B. , LaPlant, Betsy R. , McPhail, Ellen D. ... - ASH - Blood - 2015

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - N1085

Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials

Google Scholar

Jones, J. A. , Stark, A. , Zhao, W. , Lin, T. S. , Rai, K. R. ... - - Blood - 2011

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - CALGB-10101 , CALGB-19901

Bortezomib maintenance (BM) or consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): 8-year follow-up of CALGB 50403 (Alliance)

Google Scholar

Kaplan, Lawrence D. , Maurer, Matthew , Stock, Wendy , Fulton, Noreen ... - ASH - Blood - 2018

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Lymphoma - CALGB-50403

Bortezomib Maintenance (Bm) Versus Consolidation (Bc) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (Asct) For Untreated Mantle Cell Lymphoma (Mcl): CALGB 50403

Google Scholar

Kaplan, Lawrence D. , Stock, Wendy , Jung, Sin-Ho , Bartlett, Nancy ... - ASH - Blood - 2015

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50403

A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia

PubMed

PMC

QxMD

Google Scholar

Khandanpour, C. , Thiede, C. , Valk, P. J. , Sharif-Askari, E. ... - - Blood - 2010

Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C9665 , C8461

Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808

Google Scholar

Kolitz, J. E. , Hars, V. , Deangelo, D. J. , Allen, S. L. ... - - Blood - 2007

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-19808 , CALGB-8461 , CALGB-9665

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

PubMed

PMC

QxMD

DOI

Google Scholar

Kolitz, Jonathan E. , George, Stephen L. , Marcucci, Guido ... - - Blood - 2010

Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19808 , CALGB-8461

Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001

Google Scholar

Koval, G. , Wetzler, M. , Watson, D. , Owzar, K. , Bloomfield, C. D. ... - - Blood - 2011

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10001

A Comparison of Outcomes between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia: North American Intergroup Study CALGB 9710 (Alliance)

Google Scholar

Kutny, Matthew A. , Geyer, Susan , Laumann, Kristina M ... - ASH - Blood - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - C9710

Effect of young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia: North American Intergroup Study CALGB 9710 (Alliance)

Google Scholar

Kutny, Matthew A. , Gregory, John , Geyer, Susan , Laumann, Kristina ... - ASH - Blood - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - C9710

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study

PubMed

PMC

QxMD

DOI

Google Scholar

Langer, Christian , Radmacher, Michael D. , Ruppert, Amy S. ... - - Blood - 2008

Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665

An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Google Scholar

Larson, Richard A. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2017

Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-10603

Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML

PubMed

PMC

QxMD

Google Scholar

Li, Z. , Huang, H. , Li, Y. , Jiang, X. , Chen, P. , Arnovitz, S. ... - - Blood - 2012

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C9665

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101

Google Scholar

Lin, T. S. , Donohue, K. A. , Byrd, J. C. , Lucas, M. S. , Hoke, E. ... - - Blood - 2009

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10101

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101

Google Scholar

Lin, T. S. , Donohue, K. A. , Lucas, M. S. , Byrd, J. C. ... - - Blood - 2007

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-10101

Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia

PubMed

PMC

QxMD

DOI

Google Scholar

Link, Daniel C. , Kunter, Ghada , Kasai, Yumi , Zhao, Yu ... - - Blood - 2007

Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-9665

Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102)

Google Scholar

Lozanski, G. , Sanford, B. , Mrozek, K. , Edwards, C. , Pearson, R. ... - ASH - Blood - 2007

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10102 , CALGB-8461 , CALGB-9665 , CALGB-9862

Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance)

Google Scholar

Malnassy, Greg , Geyer, Susan , Fulton, Noreen , Koval, Greg ... - - Blood - 2013

Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leuk Corr Sci - CALGB-10403 , CALGB-59909

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

PubMed

PMC

QxMD

DOI

Google Scholar

Mantha, Simon , Goldman, Debra A. , Devlin, Sean M. , Lee, Ju-Whei ... - - Blood - 2017

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-9710

Gene and microRNA (miRNA) Expression Signatures and Prognostic Significance of CEBPA Mutations in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML) with High-Risk Molecular Features: A Cancer and Leukemia Group B (CALGB) Study

Google Scholar

Marcucci, G. , Maharry, K. , Radmacher, M. D. , Mrozek, K. ... - - Blood - 2007

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20205 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665

Adding the KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB study 10801 (Alliance)

Google Scholar

Marcucci, Guido , Geyer, Susan , Zhao, John , Caroll, Andrew J ... - ASH - Blood - 2014

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10801

Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study

Google Scholar

Marcucci, Guido , Geyer, Susan , Zhao, John , Caroll, Andrew J ... - ASH - Blood - 2013

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10801

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

PubMed

PMC

QxMD

DOI

Google Scholar

Martin, Peter , Bartlett, Nancy L. , Blum, Kristie A. , Park, Steven ... - - Blood - 2019

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Lymphoma - NCT02159755

Oral Azacitidine (CC-486) Plus R-CHOP in Patients With High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

DOI

Google Scholar

Martin, Peter , Bartlett, Nancy L. , Chavez, Julio C. ... - ASH - Blood - 2018

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - AFT-08 , NCT02343536

A phase I, open–label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3b follicular lymphoma, or transformed lymphoma (AFT-08)

Google Scholar

Martin, Peter , Bartlett, Nancy L. ... - ASH - Blood - 2017

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - NCT02343536 , AFT-08

Diagnosis to treatment interval (DTI) is associated with adverse outcome in newly diagnosed patients with mantle cell lymphoma, a MER/LEO and Alliance collaboration

Google Scholar

Maurer, Matthew J. , Ruppert, Amy S. , Link, Brian K. ... - ASH - Blood - 2018

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - A151814

Survival analysis from the CALGB trial of lenalidomide (LEN) maintenance therapy in newly diagnosed multiple myeloma (NDMM) post-autologous stem cell transplant (ASCT), adjusting for crossover (Alliance)

DOI

Google Scholar

McCarthy, Philip L. , Suman, Vera , Cooper, Miranda , Saunders, Owain ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Myeloma - CALGB-100104

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Google Scholar

Mccarthy, P. L. , Owzar, K. , Anderson, K. C. , Hofmeister, C. C. ... - - Blood - 2010

Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-100104

ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet 'Favorable' Genetic Category

Google Scholar

Metzeler, K. H. , Becker, H. , Maharry, K. , Radmacher, M. D. ... - - Blood - 2011

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461 , CALGB-9665

An 86-Probe Gene Expression Signature Can Predict Survival in AML with Normal Karyotype Independently of FLT3 ITD and NPM1 Mutation Status - A Collaborative Study from the AMLCG and CALGB Study Groups

Google Scholar

Metzeler, K. H. , Hummel, M. , Bloomfield, C. D. , Spiekermann, K. ... - - Blood - 2007

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-9621 , CALGB-9665

Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study

Google Scholar

Metzeler, K. H. , Maharry, K. , Radmacher, M. D. , Mrozek, K. ... - - Blood - 2010

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , C8641 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

PubMed

PMC

QxMD

DOI

Google Scholar

Metzeler, Klaus H. , Becker, Heiko , Maharry, Kati ... - - Blood - 2011

Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461 , CALGB-9665

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

PubMed

PMC

QxMD

DOI

Google Scholar

Metzeler, Klaus H. , Hummel, Manuela , Bloomfield, Clara D. ... - - Blood - 2008

Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-9621 , CALGB-9665

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

PubMed

PMC

QxMD

DOI

Google Scholar

Micallef, Ivana N. M. , Maurer, Matthew J. , Wiseman, Gregory A. ... - - Blood - 2011

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - N0489

Development and Validation of a Dominant Clone Precision Medicine Classification for Treatment of Elderly Acute Myeloid Leukemia (Alliance)

DOI

Google Scholar

Mims, Alice S. , Borate, Uma , Kohlschmidt, Jessica , Norris, Brianna ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , CALGB-20202

Comparisons between TP53 mutations and TP73 mutations in adult acute myeloid leukemia (AML) (Alliance)

DOI

Google Scholar

Mims, Alice S. , Kohlschmidt, Jessica , Eisfeld, Ann-Kathrin ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , CALGB-20202

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222

PubMed

PMC

QxMD

DOI

Google Scholar

Moore, Joseph O. , George, Stephen L. , Dodge, Richard K. ... - - Blood - 2005

Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-9222

Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901)

Google Scholar

Morrison, V. A. , Peterson, B. L. , Rai, K. R. , Byrd, J. C. ... - ASH - Blood - 2007

Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leukemia - C9011 , CALGB-19901 , CALGB-9712

Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes in Adults: a Cancer and Leukemia Group B (CALGB) Study

Google Scholar

Mrozek, K. , Holland, K. B. , Pettenati, M. J. , Maharry, K. ... - ASH - Blood - 2009

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - Comprehensive

Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts)

Google Scholar

Mrozek, K. , Marcucci, G. , Maharry, K. , Nicolet, D. , Becker, H. ... - - Blood - 2011

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

Molecular landscape and clinical features of acute myeloid leukemia (AML) with complex karyotype (CK) CALGB 20202 and 8461 (Alliance)

Google Scholar

Mrózek, Krzysztof , Eisfeld, Ann-Kathrin , Kohlschmidt, Jessica ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

PubMed

PMC

QxMD

DOI

Google Scholar

Mrózek, Krzysztof , Marcucci, Guido , Paschka, Peter ... - - Blood - 2007

Manuscript - No-Endpoint Endpoint - Other Analysis - Leuk Corr Sci -

Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL)

Google Scholar

Muffly, L. S. , Stock, W. , Breitenbach, K. , Mulkey, F. , Luger, S. ... - ASH - Blood - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Disparities - CALGB-10403 , C10403

Concomitant use of midostaurin with Strong CYP3A4 inhibitors: An analysis from the CALGB 10603/RATIFY Trial (Alliance)

Google Scholar

Ouatas, Taoufik , Duval, Vincent , Sinclair, Karen ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603

Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Google Scholar

Papaioannou, Dimitrios , Maharry, Kati , Mrózek, Krzysztof ... - ASH - Blood - 2013

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-9665 , CALGB-8461

Recurrent Genetic Variants of Long Non-Coding RNAs Independently Associate with Clinical Outcome of Younger Adults with Cytogenetically Normal Acute Myeloid Leukemia (ALLIANCE/CALGB 8461, 9665, 20202)

Google Scholar

Papaioannou, Dimitrios , Ozer, Gulcin H. , Nicolet, Deedra ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461 , CALGB-9665

Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study

Google Scholar

Paschka, P. , Marcucci, G. , Ruppert, A. S. , Mrozek, K. ... - - Blood - 2007

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665

Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710

Google Scholar

Powell, B. L. , Moser, B. K. , Stock, W. , Gallagher, R. E. ... - - Blood - 2011

Abstract - Secondary Endpoint - Primary Analysis - Leukemia - C9710

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710

PubMed

PMC

QxMD

DOI

Google Scholar

Powell, Bayard L. , Moser, Barry , Stock, Wendy ... - - Blood - 2010

Manuscript - Primary Endpoint - Primary Analysis - Leukemia - C9710

Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

Google Scholar

Rai, K. R. , Peterson, B. L. , Appelbaum, F. R. , Tallman, M. S. ... - ASH - Blood - 2009

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Leukemia - C9011

Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt - Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

Google Scholar

Rizzieri, D. A. , Johnson, J. L. , Byrd, J. C. , Lozanski, G. ... - - Blood - 2010

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10002

Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)

Google Scholar

Rosenbaum, Cara A. , Pitcher, Brandelyn , Bartlett, Nancy L ... - ASH - Blood - 2015

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50901

Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202

Google Scholar

Rubenstein, J. L. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2010

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50202

Prognostic impact of insertion site in acute myeloid leukemia with FLT3 internal tandem duplication: results from the RATIFY study (Alliance)

DOI

Google Scholar

Rücker, Frank G. , Du, Ling , Blätte, Tamara J. , Benner, Axel ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603

Aberrant Gene Expression of BAALC and ERG in Older >= 60 Years (y) De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study

Google Scholar

Schwind, S. , Marcucci, G. , Maharry, K. , Mrozek, K. ... - - Blood - 2009

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10201 , CALGB-20202 , CALGB-8461 , CALGB-9720

inv(16)/t(16;16) acute myeloid leukemia with non–type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations

PubMed

PMC

QxMD

DOI

Google Scholar

Schwind, Sebastian , Edwards, Colin G. , Nicolet, Deedra ... - - Blood - 2013

Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-8525 , CALGB-8821 , CALGB-8923 , CALGB-9022 , CALGB-9120 , CALGB-9222 , CALGB-9621 , CALGB-9720 , CALGB-19808 , CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603

Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients (Pts) with advanced indolent NHL and CLL: CALGB 109901

Google Scholar

Shea, T. C. , Johnston, J. , Walsh, W. , Farag, S. , Mccarty, J. ... - - Blood - 2007

Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-109901

Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: Alliance A051201 and A051202

Google Scholar

Smith, Sonali M. , Pitcher, Brandelyn N. , Jung, Sin-Ho ... - ASH - Blood - 2014

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - A051201 , A051202

Interfollicular CD10 Expression and Follicular PD1 Tumor-infiltrating lymphocytes as biologic risk factors in patients with previously untreated follicular lymphoma receiving rituximab-based biologic therapy: An Alliance correlative science study (CALGB 50901, 50402, 50701, 50803, 50401)

Google Scholar

Sohani, Aliyah R. , Pitcher, Brandy , Chadburn, Amy , Said, Jonathan ... - ASH - Blood - 2015

Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Correl Sci NOS - CALGB-50401 , CALGB-50402 , CALGB-50701 , CALGB-50803 , CALGB-50901

Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102)

Google Scholar

Stock, W. , Sanford, B. , Lozanski, G. , Vij, R. , Byrd, J. C. ... - ASH - Blood - 2009

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10102

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

PubMed

PMC

QxMD

DOI

Google Scholar

Stock, Wendy , La, Mei , Sanford, Ben , Bloomfield, Clara D. ... - - Blood - 2008

Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leukemia - CALGB-8811 , CALGB-9331 , CALGB-19802 , CALGB-8461 , CALGB-9111 , CALGB-9511

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

PubMed

PMC

QxMD

DOI

Google Scholar

Stock, Wendy , Luger, Selina M. , Advani, Anjali S. , Yin, Jun ... - - Blood - 2019

Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10403

Favorable outcomes for adolescents and young adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early results of US Intergroup trial CALGB 10403 (Alliance)

Google Scholar

Stock, Wendy , Luger, Selina , Advani, Anjali , Geyer, Susan ... - ASH - Blood - 2014

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - C10403 , CALGB-10403

The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Google Scholar

Stone, Richard M. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603

Midostaurin v Placebo plus Daunorubicin/Cytarabine Induction, High-dose Cytarabine Consolidation and Maintenance Therapy in Newly Diagnosed Acute Myeloid Leukemia ( AML) Patients ( pts) age 18-60 with FLT3 mutations: An International Prospective Randomized Placebo-Controlled Double-Blind Trial (CALGB 10603 [Alliance])

Google Scholar

Stone, Richard M. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2015

Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-10603

Doxorubicin, vinblastine and gemcitabine (AVG), a novel regimen excluding bleomycin for the treatment of early stage Hodgkin Lymphoma (HL): Results of CALGB 50203

Google Scholar

Straus, D. J. , Lacasce, A. S. , Juweid, M. E. , Kostakoglu, L. ... - - Blood - 2007

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50203

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

PubMed

PMC

QxMD

DOI

Google Scholar

Straus, David J. , Johnson, Jeffrey L. , LaCasce, Ann S. ... - - Blood - 2011

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50203

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

PubMed

PMC

QxMD

DOI

Google Scholar

Straus, David J. , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Blood - 2018

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50604

Results of US Intergroup Trial of Response-Adapted Chemotherapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

Google Scholar

Straus, David J. , Pitcher, Brandelyn N. , Kostakoglu, Lale ... - ASH - Blood - 2015

Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - CALGB-50604

Toxicities and related outcomes of elderly patients (≥65 years) with hematologic malignancies in the contemporary era (Alliance A151611)

Google Scholar

Tallarico, Michael , Foster, Jared , Seisler, Drew ... - ASH - Blood - 2016

Abstract - Primary Endpoint - Comprehensive Analysis - Older Adult - CALGB-10101 , A151611 , CALGB-10404 , CALGB-10501 , CALGB-19805 , CALGB-19901 , CALGB-50002 , CALGB-50103 , CALGB-50201 , CALGB-50401 , CALGB-50402 , CALGB-50501 , CALGB-50602 , CALGB-50701 , CALGB-50803

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

PubMed

PMC

QxMD

Google Scholar

Tallman, M. S. , Kim, H. T. , Montesinos, P. , Appelbaum, F. R. ... - - Blood - 2010

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - INT-0129

The high prevalence of FLT3-ITD mutations is associated with the poor outcome in adult patients with t(6;9)(p23;q34) positive AML - Results of an international metaanalysis

Google Scholar

Thiede, C. , Bloomfield, C. D. , Lo Coco, F. , Frohling, S. ... - ASH - Blood - 2007

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-8461 , CALGB-9621 , CALGB-9665

FLT3 mutation assay laboratory cross validation: results from the CALGB 10603/RATIFY(Alliance) trial in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML)

DOI

Google Scholar

Thiede, Christian , Prior, Thomas , Coco, Francesco Lo ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

PubMed

PMC

QxMD

DOI

Google Scholar

Ujjani, Chaitra S. , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Blood - 2016

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - A051103

Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)

Google Scholar

Ujjani, Chaitra , Jung, Sin-Ho , Pitcher, Brandelyn , Martin, Peter ... - ASH - Blood - 2015

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - A051103

Allogeneic Hematopoietic Cell Transplantation (HCT) vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG and CIBMTR Study

Google Scholar

Ustun, Celalettin , Le-Rademacher, Jennifer G , Wang, Hailin ... - ASH - Blood - 2018

Abstract - Primary Endpoint - Primary Analysis - Leukemia - A151509 , CALGB-100103

Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults With FLT3-ITD Mutated AML (Alliance C11001).

Google Scholar

Uy, Geoffrey L. , Mandrekar, Sumithra , Laumann, Kristina ... - ASH - Blood - 2015

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-11001

Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001)

Google Scholar

Uy, Geoffrey L. , Sanford, Ben , Marcucci, Guido , Zhao, Weiqiang ... - ASH - Blood - 2013

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-11001

CALGB 100801 (Alliance): A phase II multi-center NCI cooperative group study of the addition of azacitidine (AZA) to reduced-intensity conditioning (RIC) allogeneic transplantation for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML): Results of a busulfan test dose strategy

Google Scholar

Vij, Ravi , Hars, Vera , Shea, Thomas , Hoke, Eva , Blum, William ... - ASH - Blood - 2014

Abstract - Secondary Endpoint - Primary Analysis - Transplant - CALGB-100801

Interim safety analysis of a phase 2 randomized study of daratumumab (dara), lenalidomide (r), bortezomib (v), and dexamethasone (d; dara‐rvd) vs. rvd in patients (pts) with newly diagnosed multiple myeloma (mm) eligible for high‐dose therapy (hdt) and autologous stem cell transplantation (asct)

Google Scholar

Voorhees, Peter M. , MD , Costa, Luciano J. , PhD , Reeves, Brandi ... - ASH - Blood - 2017

Abstract - Secondary Endpoint - Preliminary Analysis - Myeloma - AFT-29

Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: Phase I results.

Google Scholar

Voorhees, Peter M. , Mulkey, Flora , Hassoun, Hani ... - ASH - Blood - 2015

Abstract - Primary Endpoint - Primary Analysis - Myeloma - A061202

Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Google Scholar

Voorhees, Peter M. , Rodriguez, Cesar , Reeves, Brandi ... - ASH - Blood - 2018

Abstract - Primary Endpoint - Primary Analysis - Myeloma - AFT-29

RATIFY: Prognostic impact of FLT3 tyrosine kinase domain (TKD) and NPM1 mutation status in patients with newly diagnosed acute myeloid leukemia (AML) treated with midostaurin or placebo plus standard chemotherapy (Alliance)

DOI

Google Scholar

Voso, Maria Teresa , Larson, Richard A. , Prior, Thomas W ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603

Uniparental Disomies (UPD) of Chromosome 13q Is Associated with Shorter Disease-Free Survival in Adult Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

DOI

Google Scholar

Walker, Christopher J. , Eisfeld, Ann-Kathrin , Kohlschmidt, Jessica ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , CALGB-20202

Genome-wide association study (GWAS) identifies a significant acute myeloid leukemia (AML) susceptibility locus near BICRA (Alliance)

DOI

Google Scholar

Walker, Christopher J. , Oakes, Christopher C. , Genutis, Luke K. ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , CALGB-20202

High resolution array-based CGH and SNP studies of AML genomes

Google Scholar

Walter, M. J. , Ries, R. , Li, X. , Shannon, W. , Payton, J. ... - ASH - Blood - 2007

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-9665

Autologous stem cell transplantation (SCT) following sequential chemotherapy and imatinib for adults with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) - CALGB study 10001

Google Scholar

Wetzler, M. , Stock, W. , Donohue, K. A. , Owzar, K. , Sher, D. A. ... - - Blood - 2007

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10001 , CALGB-8461 , CALGB-9665 , CALGB-9862

Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)

Google Scholar

Wetzler, M. , Watson, D. , Stock, W. , Owzar, K. , Koval, G. , Hoke, E. ... - - Blood - 2012

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10001

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

PubMed

PMC

QxMD

DOI

Google Scholar

Wetzler, Meir , Sanford, Ben L. , Kurtzberg, Joanne ... - - Blood - 2007

Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-9511

Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older >= 60 Years (Y) De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study

Google Scholar

Whitman, S. P. , Maharry, K. , Radmacher, M. D. , Mrozek, K. ... - - Blood - 2009

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10201 , CALGB-20202 , CALGB-8461 , CALGB-9720

Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance)

Google Scholar

Whitman, S. , Kohlschmidt, J. , Maharry, K. , Nicolet, D. ... - - Blood - 2012

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-9665 , CALGB-20202

DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication

PubMed

PMC

QxMD

DOI

Google Scholar

Whitman, Susan P. , Hackanson, Björn , Liyanarachchi, Sandya ... - - Blood - 2008

Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20502 , CALGB-9665 , CALGB-9769

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

PubMed

PMC

QxMD

DOI

Google Scholar

Whitman, Susan P. , Maharry, Kati , Radmacher, Michael D. ... - - Blood - 2010

Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , C8525 , CALGB-10201 , CALGB-8923 , CALGB-9420 , CALGB-9720

A phase II study of dasatinib and dexamethasone as primary therapy followed by hematopoietic cell transplantation for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: CALGB Study 10701 (Alliance)

Google Scholar

Wieduwilt, Matthew J. , Yin, Jun , Wetzler, Meir , Uy, Geoff ... - ASH - Blood - 2016

Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-10701

A phase II study of dasatinib and dexamethasone as primary therapy followed by transplantation for adults with newly diagnosed PH/BCR-ABL1-positive acute lymphoblastic leukemia: Final results of Alliance/CALGB study 10701

Google Scholar

Wieduwilt, Matthew J. , Yin, Jun , Wetzler, Meir , Uy, Geoff ... - ASH - Blood - 2018

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10701

Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: Alliance/CALGB 50303

Google Scholar

Wilson, Wyndham H. , Jung, Sin-Ho , Pitcher, Brandelyn , Hsi, Eric ... - ASH - Blood - 2016

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50303

Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies

Google Scholar

Woyach, J. A. , Ruppert, A. S. , Peterson, B. , Rai, K. R. ... - - Blood - 2011

Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leukemia - C9011 , CALGB-10101 , CALGB-9712

Treatment with fludarabine and rituximab produces extended remissions and survival in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: Long-term follow up of CALGB study 9712

Google Scholar

Woyach, J. , Heerema, N. A. , Stark, A. , Peterson, B. L. ... - - Blood - 2009

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-9712

Ibrutinib alone or in combination with rituximab produces superior progression free survival compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia: Results of Alliance A041202

DOI

Google Scholar

Woyach, Jennifer A. , Ruppert, Amy S. , Heerema, Nyla ... - ASH - Blood - 2018

Abstract - Primary Endpoint - Primary Analysis - Leukemia - A041202

Event-free survival as a surrogate endpoint for overall survival in previously untreated acute myeloid leukemia: An individual patient-level analysis of multiple randomized trials (Alliance A151614)

DOI

Google Scholar

Yin, Jun , LaPlant, Betsy , Storrick, Elizabeth , Uy, Geoffrey L. ... - ASH - Blood - 2018

Abstract - Primary Endpoint - Comprehensive Analysis - Leukemia - A151614 , CALGB-10201 , E1900 , CALGB-10603 , S0106